Novartis’ Multiple Sclerosis Pill Faces FDA Review (Update1) - BusinessWeek
Novartis AG’s drug Gilenia has risks that may outweigh its benefit in treating multiple sclerosis, according to U.S. regulators reviewing whether to approve the first pill to slow progression of the disease.
1 comment:
I've had MS since 1995. (At least that was when I was diagnosed.) Although I understand why people would be excited about this new pill, the prospect of cancer terrifies me. For now, at least, I'll stick with Copaxone.
Post a Comment